Article in Science (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Gaurav AgarwalDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-6710-8652
Mateusz AntoszewskiDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-7651-0547
Xueqin XieMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yash PershadDivision of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-2282-1403
Uma P AroraDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Chi-Lam PoonComputational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Peng LyuDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-3281-7560
Andrew J LeeDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-9917-8834
Chun-Jie GuoDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Tianyi YeDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-8242-5242
Laila Barakat NorfordDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0009-0006-9224-3625
Anna-Lena NeehusDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-8573-6820
Lucrezia Della VolpeDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-9087-1293
Lara WahlsterDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-8409-7580
Diyanath RanasingheTranslational and Clinical Research Institute, Newcastle University Centre for Cancer, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0001-5151-8908
Tzu-Chieh HoMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-2913-9319
Trevor S BarloweMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0009-0002-1507-3539
Arthur ChowMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-4922-0410
Alexandra SchurerMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-8028-838X
James TaggartMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Benjamin H DurhamMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-8090-5448
Omar Abdel-WahabMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-3907-6171
Kathy L McGrawImmune Deficiency Cellular Therapy Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
James M AllanTranslational and Clinical Research Institute, Newcastle University Centre for Cancer, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0002-7580-5087
Ruslan SoldatovComputational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-5670-5881
Alexander G BickDivision of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0001-5824-9595
Michael G KharasMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-1165-6991
Vijay G SankaranDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-0044-443X
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4M
Stem Cell and Transplantation BiologyU54DK106829 · NIDDK · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DEREK L STIREWALT · 2015 to 2026
$9.1M
Mechanisms of epitranscriptomic regulation in cancerR01CA186702 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SAMIE R JAFFREY, Michael Kharas · 2014 to 2026
$8.0M
Clonal Hematopoiesis Aging Resiliency MechanismsR01AG088657 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Alexander Bick, Siddhartha Jaiswal · 2024 to 2026
$6.6M
Uncovering the role for MSI2 network in hematopoietic stem cellsR01DK101989 · NIDDK · SLOAN-KETTERING INST CAN RESEARCH · PI Michael Kharas, Vijay Ganesh Sankaran · 2014 to 2026
$6.2M
Systematic Genetic Dissection of Human ErythropoiesisR01DK103794 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI Vijay Ganesh Sankaran · 2014 to 2026
$5.9M
Next generation functional genomics of hematology traitsR01HL146500 · NHLBI · UNIVERSITY OF WASHINGTON · PI ALEXANDER P REINER · 2020 to 2026
$5.7M
Characterizing the MSI2 network in leukemiaR01CA193842 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KHARAS, MICHAEL · 2015 to 2025
$4.1M
Identification of therapeutic targets for leukemia stem cells in AML-iPSC modelsR01CA225231 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KHARAS, MICHAEL, PAPAPETROU, EIRINI · 2018 to 2022
$3.2M
Interrogation of the oxidative-stress-induced leukemia program in vivo usingmetabolic imagingR01CA283578 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Kayvan R Keshari, Michael Kharas · 2023 to 2026
$3.0M
Molecular and genetic analysis of novel Slicer-dependent miRNA pathways in bloodR01HL135564 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI KHARAS, MICHAEL, LAI, ERIC C · 2017 to 2020
$2.9M
Establishing the dynamics of lymphoid clonal hematopoiesis and its aging-related disease consequencesR01AG083736 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul L. Auer, Alexander Bick · 2023 to 2026
Somatic mutations that increase the fitness of hematopoietic stem cells (HSCs) drive their expansion in clonal hematopoiesis (CH) and predispose individuals to blood cancers. Population variation in the growth rate and potential of mutant clones suggests that genetic factors may confer resilience against CH. Here, we identified a noncoding regulatory variant, rs17834140-T, that protects against CH and myeloid malignancies by selectively down-regulating the RNA-binding protein MSI2 in HSCs. By modeling variant effects and mapping MSI2 binding targets, we uncovered an RNA network that maintains human HSCs and influences CH risk. Variant rs17834140-T was associated with slower CH expansion, and stem cell MSI2 levels modified
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Inherited resilience to clonal hematopoiesis by modifying stem cell RNA regulation. · full record | OpenQuestion